Med­i­cal re­search sup­ported by Fun­da­cion MAPFRE pro­vides en­cour­ag­ing re­sults

Malta Independent - - BUSINESS & FINANCE -

Fundación MAPFRE has pub­licly pre­sented the re­sults of the first clin­i­cal trial of per­son­al­ized cell ther­apy in pa­tients with com­plete and chronic spinal cord in­jury, con­ducted by the team of neu­ro­sur­geon Dr. Jesús Va­quero from the Puerta de Hierro Univer­sity Hospi­tal in Ma­jada­honda, Spain.

The op­er­a­tion per­formed by the mul­ti­dis­ci­plinary team from the cen­ter in­volves im­plant­ing mes­enchy­mal stem cells, which can cre­ate dif­fer­ent types of tis­sue, from the ac­tual pa­tient in the ex­act lo­ca­tion of the spinal cord in­jury. This tech­nique is cus­tom­ized for each pa­tient.

The re­sults ob­tained after this first trial started in July 2013, pub­lished in the sci­en­tific jour­nal Cy­tother­apy, and which in­volved 12 pa­tients, are en­cour­ag­ing. There was an im­prove­ment in sen­si­tiv­ity and spas­tic­ity (mus­cle stiff­ness) in all cases, an im­prove­ment in bowel and blad­der con­trol in more than 80 per­cent of pa­tients, an im­prove­ment in sex­ual func­tion­ing and neu­ro­pathic pain (ab­nor­mal per­cep­tion of pain); in this case, through a disor­der in the cen­tral ner­vous sys­tem) and mo­tor func­tion re­cov­ery in more than 50 per­cent of pa­tients.

This clin­i­cal trial is the re­sult of over 20 years of re­search that has been done with the sup­port of var­i­ous or­ga­ni­za­tions, such as Fundación MAPFRE and the Rafael del Pino Foun­da­tion.

Fundación MAPFRE was the first or­ga­ni­za­tion to firmly com­mit to this project. It has con­tributed from the out­set to fi­nanc­ing stud­ies and clin­i­cal tri­als that have been nec­es­sary and has borne wit­ness to the ef­forts and progress that has been made, and the or­ga­ni­za­tion, which in re­cent years has sup­ported more than 800 re­search projects world­wide, has in­vested ap­prox­i­mately 1.5 mil­lion eu­ros in this project.

Trau­matic spinal cord in­jury rep­re­sents one of the great­est med­i­cal and so­cial prob­lems, with no ef­fec­tive ther­a­pies ca­pa­ble of restor­ing the neu­ro­log­i­cal se­que­lae aris­ing as a re­sult of it.

Mapfre Mid­dle­sea (C-5553) is au­tho­rised by the Malta Fi­nan­cial Ser­vices Author­ity to carry on both Long Term and Gen­eral Business un­der the In­sur­ance Business Act, 1998.

Newspapers in English

Newspapers from Malta

© PressReader. All rights reserved.